Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis - Pilot Phase (ATTEST).

Next Previous
X
Search
Trial Profile

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis - Pilot Phase (ATTEST).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenecteplase (Primary) ; Alteplase
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ATTEST

    • Most Recent Events

    • 19 Mar 2021 Systemic review and meta-analysis this and 3 other studies (EXTEND-IA, AUSTRALIAN TNK & TAAIS), presented at the International Stroke Conference 2021.
    • 04 Dec 2020 Results comparing the efficacy and safety outcomes of intravenous tenecteplase to intravenous alteplase administration for acute ischemic stroke patients with large vessel occlusions from 4 trials, published in the Stroke
    • 13 Dec 2016 Results of pooled post-hoc analysis from TAAIS and ATTEST studies (n=146) published in the Circulation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top